| A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors (NCT05470348) | Sichuan Baili Pharmaceutical Co., Ltd. | 2022-08-11 |
| A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) (NCT05192486) | Sichuan Baili Pharmaceutical Co., Ltd. | 2022-08-10 |
| A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors (NCT05461768) | Sichuan Baili Pharmaceutical Co., Ltd. | 2022-08-09 |
| A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors (NCT05385692) | Sichuan Baili Pharmaceutical Co., Ltd. | 2022-06-01 |
| A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors (NCT05339685) | Sichuan Baili Pharmaceutical Co., Ltd. | 2022-05-20 |
| A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors (NCT05393427) | Sichuan Baili Pharmaceutical Co., Ltd. | 2022-02-15 |
| A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor (NCT05262491) | Sichuan Baili Pharmaceutical Co., Ltd. | 2022-02-14 |
| A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy (NCT05104775) | Sichuan Baili Pharmaceutical Co., Ltd. | 2022-02-09 |
| SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. (NCT05020769) | Sichuan Baili Pharmaceutical Co., Ltd. | 2022-01-06 |
| A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC (NCT05054439) | Sichuan Baili Pharmaceutical Co., Ltd. | 2021-12-22 |
| SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. (NCT05022654) | Sichuan Baili Pharmaceutical Co., Ltd. | 2021-12-13 |
| SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. (NCT05020457) | Sichuan Baili Pharmaceutical Co., Ltd. | 2021-12-07 |
| SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies (NCT05039944) | Sichuan Baili Pharmaceutical Co., Ltd. | 2021-11-30 |
| A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor (NCT05194982) | Sichuan Baili Pharmaceutical Co., Ltd. | 2021-11-29 |
| A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer (NCT05160545) | Sichuan Baili Pharmaceutical Co., Ltd. | 2021-11-26 |
| A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC (NCT05044897) | Sichuan Baili Pharmaceutical Co., Ltd. | 2021-10-20 |
| A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors (NCT05039931) | Sichuan Baili Pharmaceutical Co., Ltd. | 2021-09-15 |
| A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (NCT04794972) | Sichuan Baili Pharmaceutical Co., Ltd. | 2021-04-14 |
| A Study of SI-F019 in Healthy Participants (NCT04851444) | Sichuan Baili Pharmaceutical Co., Ltd. | 2021-03-30 |
| A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors (NCT04606472) | Sichuan Baili Pharmaceutical Co., Ltd. | 2020-11-10 |
| Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia (NCT04606433) | Sichuan Baili Pharmaceutical Co., Ltd. | 2020-11-04 |
| A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors (NCT04603287) | Sichuan Baili Pharmaceutical Co., Ltd. | 2020-04-17 |
| Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection (NCT03853369) | Sichuan Baili Pharmaceutical Co., Ltd. | 2019-02-18 |
| Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection. (NCT03855826) | Sichuan Baili Pharmaceutical Co., Ltd. | 2019-01-15 |